MedTrace Logo

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

NCT03995472 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-09-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.

Conditions

  • Advanced Malignancies

Interventions

DRUG

SHR-1501

Administered subcutaneously

DRUG

SHR-1316

Administered intravenously

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yilong Wu, MD · Guangdong General Hospital & Guangdong Academy of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-14
Primary Completion
2023-01-12
Completion
2023-01-12

Countries

  • Australia
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03995472 on ClinicalTrials.gov